ATM and hepatocellular carcinoma: To further confirm that aPKC-ι is the downstream effector of P300, we treated the HCC cells with 15 μmol/L of ATM, an inhibitor of aPKC-ι, after P300 knockdown and aPKC-ι rescue10.